Clinical Trial Update: TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating transarterial chemoembolization with sorafenib for advanced hepatocellular carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED